2026 Q2 - tulosraportti
44 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 583 | - | - | ||
| 992 | - | - | ||
| 1 537 | - | - | ||
| 617 | - | - | ||
| 1 447 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenSpeulative update from "my" 24/7 agent: Circio – potentially undervalued ESGCT trigger An interesting track before ESGCT October 27–28: September 1, Circio confirmed that they already had long-term circVec expression in the spleen after T-cell targeted LNPs, but lacked the analysis that could determine whether the expression actually came from the T cells. At the same time, the CTO stated that the necessary analysis equipment would be in place in September, and that this had high priority. Thus, it is entirely possible that this analysis is now completed and can be included in the ESGCT presentation on next-generation T-cell therapies. My assessment: - Analysis completed within ESGCT: ~75 % - Confirmed expression in T cells: ~65 % - New T-cell data at ESGCT: ~45 % If long-term circVec expression is specifically confirmed in T cells at a low LNP dose, I think previous +15–30 % becomes too conservative. For a small biotech company where in-vivo CAR-T has become a main driver, +30–60 % may be more realistic with truly strong data. This could be one of the most important things to follow October 27–28.
Doesn't that qualify as price-sensitive information? If they share it before the presentation with ESGCT/a limited number of participants, then that would surely be in the grey area or illegal?- ·5 t sittenAlltid gøyalt å spekulere i hvem partnerne er. Beg å se sammenhenger overalt😅 Men uansett fin nyhet for de spesielt interesserte: https://www.biospace.com/press-releases/arexera-therapeutics-formerly-atalanta-therapeutics-unveils-new-corporate-identity-and-advances-huntingtons-disease-franchiseArexera: Increased focus on RNA treatment for Huntington's disease strengthens interest in RNA technology. Circio – ESGCT October 27–30: Three abstracts, including one oral presentation and two posters. Data on circVec and next-generation T-cell therapy will be published starting October 27.  Potential trigger: New CAR-T and disease model data will strengthen interest from Big Pharma Upside: Strong financing until 2030 and documented circVec potential allow for significant value creation if upcoming data confirm the technology. 
·8 t sittenIt is always touching to see how large pharmaceutical companies speak warmly about the value of their own internal research... ...until they spot the acquisition pile, lose all self-control and shove their entire face right into it. Efficient. Risk-minimizing. And strangely enough, exactly what happens every single time.- ·11 t sitten · MuokattuListed companies normally report to the market 4 times a year. Some only have requirements for every half-year as Circio has had. They have nevertheless had 2 R&D updates in addition - in November and February/March. In addition come disclosable news. Participation in important bioconferences where news is presented are examples. Circio shareholders must take this regime in over themselves. There have been 4 equity issues the last year to secure financing and many R&D collaborations have been entered into and agreements have been stock exchange announced. There has apart from this been extensive marketing through participation in conferences 2 in the USA and in China as well as Europe just since September 1st. The program has been incredibly tight for management. Thinking there is a need now for some "office work", analyze results, follow up the contact network and prepare for ESGCT. They have signaled significant news and there is no reason not to have great expectations for ESGCT and the presentation in November. Lurking behind is Big Pharma. Bio is complex and the quality cannot be slurred with. Then one is quickly exposed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
44 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenSpeulative update from "my" 24/7 agent: Circio – potentially undervalued ESGCT trigger An interesting track before ESGCT October 27–28: September 1, Circio confirmed that they already had long-term circVec expression in the spleen after T-cell targeted LNPs, but lacked the analysis that could determine whether the expression actually came from the T cells. At the same time, the CTO stated that the necessary analysis equipment would be in place in September, and that this had high priority. Thus, it is entirely possible that this analysis is now completed and can be included in the ESGCT presentation on next-generation T-cell therapies. My assessment: - Analysis completed within ESGCT: ~75 % - Confirmed expression in T cells: ~65 % - New T-cell data at ESGCT: ~45 % If long-term circVec expression is specifically confirmed in T cells at a low LNP dose, I think previous +15–30 % becomes too conservative. For a small biotech company where in-vivo CAR-T has become a main driver, +30–60 % may be more realistic with truly strong data. This could be one of the most important things to follow October 27–28.Doesn't that qualify as price-sensitive information? If they share it before the presentation with ESGCT/a limited number of participants, then that would surely be in the grey area or illegal?
- ·5 t sittenAlltid gøyalt å spekulere i hvem partnerne er. Beg å se sammenhenger overalt😅 Men uansett fin nyhet for de spesielt interesserte: https://www.biospace.com/press-releases/arexera-therapeutics-formerly-atalanta-therapeutics-unveils-new-corporate-identity-and-advances-huntingtons-disease-franchiseArexera: Increased focus on RNA treatment for Huntington's disease strengthens interest in RNA technology. Circio – ESGCT October 27–30: Three abstracts, including one oral presentation and two posters. Data on circVec and next-generation T-cell therapy will be published starting October 27.  Potential trigger: New CAR-T and disease model data will strengthen interest from Big Pharma Upside: Strong financing until 2030 and documented circVec potential allow for significant value creation if upcoming data confirm the technology. 
- ·8 t sittenIt is always touching to see how large pharmaceutical companies speak warmly about the value of their own internal research... ...until they spot the acquisition pile, lose all self-control and shove their entire face right into it. Efficient. Risk-minimizing. And strangely enough, exactly what happens every single time.
- ·11 t sitten · MuokattuListed companies normally report to the market 4 times a year. Some only have requirements for every half-year as Circio has had. They have nevertheless had 2 R&D updates in addition - in November and February/March. In addition come disclosable news. Participation in important bioconferences where news is presented are examples. Circio shareholders must take this regime in over themselves. There have been 4 equity issues the last year to secure financing and many R&D collaborations have been entered into and agreements have been stock exchange announced. There has apart from this been extensive marketing through participation in conferences 2 in the USA and in China as well as Europe just since September 1st. The program has been incredibly tight for management. Thinking there is a need now for some "office work", analyze results, follow up the contact network and prepare for ESGCT. They have signaled significant news and there is no reason not to have great expectations for ESGCT and the presentation in November. Lurking behind is Big Pharma. Bio is complex and the quality cannot be slurred with. Then one is quickly exposed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 583 | - | - | ||
| 992 | - | - | ||
| 1 537 | - | - | ||
| 617 | - | - | ||
| 1 447 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
44 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenSpeulative update from "my" 24/7 agent: Circio – potentially undervalued ESGCT trigger An interesting track before ESGCT October 27–28: September 1, Circio confirmed that they already had long-term circVec expression in the spleen after T-cell targeted LNPs, but lacked the analysis that could determine whether the expression actually came from the T cells. At the same time, the CTO stated that the necessary analysis equipment would be in place in September, and that this had high priority. Thus, it is entirely possible that this analysis is now completed and can be included in the ESGCT presentation on next-generation T-cell therapies. My assessment: - Analysis completed within ESGCT: ~75 % - Confirmed expression in T cells: ~65 % - New T-cell data at ESGCT: ~45 % If long-term circVec expression is specifically confirmed in T cells at a low LNP dose, I think previous +15–30 % becomes too conservative. For a small biotech company where in-vivo CAR-T has become a main driver, +30–60 % may be more realistic with truly strong data. This could be one of the most important things to follow October 27–28.Doesn't that qualify as price-sensitive information? If they share it before the presentation with ESGCT/a limited number of participants, then that would surely be in the grey area or illegal?
- ·5 t sittenAlltid gøyalt å spekulere i hvem partnerne er. Beg å se sammenhenger overalt😅 Men uansett fin nyhet for de spesielt interesserte: https://www.biospace.com/press-releases/arexera-therapeutics-formerly-atalanta-therapeutics-unveils-new-corporate-identity-and-advances-huntingtons-disease-franchiseArexera: Increased focus on RNA treatment for Huntington's disease strengthens interest in RNA technology. Circio – ESGCT October 27–30: Three abstracts, including one oral presentation and two posters. Data on circVec and next-generation T-cell therapy will be published starting October 27.  Potential trigger: New CAR-T and disease model data will strengthen interest from Big Pharma Upside: Strong financing until 2030 and documented circVec potential allow for significant value creation if upcoming data confirm the technology. 
- ·8 t sittenIt is always touching to see how large pharmaceutical companies speak warmly about the value of their own internal research... ...until they spot the acquisition pile, lose all self-control and shove their entire face right into it. Efficient. Risk-minimizing. And strangely enough, exactly what happens every single time.
- ·11 t sitten · MuokattuListed companies normally report to the market 4 times a year. Some only have requirements for every half-year as Circio has had. They have nevertheless had 2 R&D updates in addition - in November and February/March. In addition come disclosable news. Participation in important bioconferences where news is presented are examples. Circio shareholders must take this regime in over themselves. There have been 4 equity issues the last year to secure financing and many R&D collaborations have been entered into and agreements have been stock exchange announced. There has apart from this been extensive marketing through participation in conferences 2 in the USA and in China as well as Europe just since September 1st. The program has been incredibly tight for management. Thinking there is a need now for some "office work", analyze results, follow up the contact network and prepare for ESGCT. They have signaled significant news and there is no reason not to have great expectations for ESGCT and the presentation in November. Lurking behind is Big Pharma. Bio is complex and the quality cannot be slurred with. Then one is quickly exposed.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 583 | - | - | ||
| 992 | - | - | ||
| 1 537 | - | - | ||
| 617 | - | - | ||
| 1 447 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt